Heart failure: erythropoietin in treatment of anemia

References (5)

1. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J 1994; 127: 674-82.
2. Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M, et al. A Canadian survey of transfusion practices in critically ill patients. Transfusion requirements in critical care investigators and the Canadian critical care trials group. Crit Care Med 1998; 26: 482-7.
3. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-44.
4. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
5. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-9.